Security key
230031106
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)
CUSIP: 230031106
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 61,075,479
- Total 13F value
- $362,176,403
- Share change
- -1,416,014
- Put/Call ratio
- 135%
- SEC-reported price per share
- $5.93
- Number of holders
- 142
- Value change
- -$12,503,675
- Number of buys
- 82
- Number of sells
- 62
- Shares outstanding
- 61,676,366
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q3 2025
Institutions
142
Top holders
10
CGEM full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 230031106
Recent filing periods:
Ownership snapshot
Top reported holders of CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
James E. Flynn
Disclosed value leader
MPM BioImpact LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 5%
13D/G row: James E. Flynn
Showing 1-6 of 15 holder rows.
Quick read
James E. Flynn leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
James E. Flynn
5%
FRANKLIN RESOURCES INC
3.8%
CITADEL ADVISORS LLC
3.4%
MPM BioImpact LLC
12%
BVF INC/IL
9.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
5%
|
$17,357,187
2,927,013 shares
|
$0 | 30 Sep 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
3.8%
|
$17,836,873
2,191,262 shares
|
$0 | 30 Sep 2024 |
| CITADEL ADVISORS LLC |
13F
13D/G
Company · Kenneth Griffin
|
3.4%
from 13D/G
|
$19,681,108
2,613,693 shares
|
— | 30 Jun 2025 |
| MPM BioImpact LLC |
13F
Company
|
12%
|
$57,591,458
7,648,268 shares
|
— | 30 Jun 2025 |
| BVF INC/IL |
13F
Company
|
9.3%
|
$43,302,643
5,750,683 shares
|
— | 30 Jun 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
7.1%
|
$33,138,340
4,400,842 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
142
Shares
61,075,479
Rows available
142
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
141
Q3 2025 holders
142
Holder diff
1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend